The biologic and small-molecule landscape for Crohn’s disease and ulcerative colitis has exploded. This edition provides updated algorithms for anti-TNF agents (infliximab, adalimumab), anti-integrins (vedolizumab), anti-IL-23 agents (risankizumab, mirikizumab), and JAK inhibitors (upadacitinib). Real-world efficacy data and safety profiles are presented in easy-to-read tables.
, making it a primary tool for those preparing for gastroenterology subspecialty exams. Clinical Utility Harrison--39-s Gastroenterology And Hepatology- 3rd Edition
The book covers a wide range of topics, including: anti-IL-23 agents (risankizumab
The textbook is written by renowned experts in the field and features: Harrison--39-s Gastroenterology And Hepatology- 3rd Edition